Dr. Shrivastava serves as the Director – Radiation Oncology at HCG ICS Khubchandani Cancer Centre.
He has been in the field of Radiation Oncology for over 40 years.
He is recognised as an expert in modern radiotherapy practice using state-of-the-art modalities, including IMRT, IGRT, stereotactic radiation, SBRT, image-guided brachytherapy & intraoperative brachytherapy, etc.
Dr. Shrivastava has handled more than 10000 cases.
He joined Tata Memorial Hospital, Mumbai in 1982. Dr. Shrivastava served as Professor and Head of the Department of Radiation Oncology, Tata Memorial Hospital for over 14 years prior to his superannuation in October 2016.
Dr. Shrivastava has over 250 research publications in peer-reviewed national and international journals and book chapters to his credit.
He is an excellent teacher, and his students are successfully practising in India and abroad. He has been the examiner in several universities in India, Sri Lanka, Indonesia, Nepal, etc.
Dr. Shyam Shrivastava occupies a leadership position in many cancer organisations nationally and internationally. He has been the President of AROI (Association of Radiation Oncologists of India), IAHOM (Indian Association of Hyperthermia in Medicine) and FARO (Federation of Asian Organisations for Radiation Oncology).
He continues to be a member and expert for various committees for several institutions in India, IAEA, WHO, etc.
Late toxicity after adjuvant conventional radiation versus Image-Guided Intensity Modulated Radiation Therapy (PARCER): A Randomised Controlled Trial. J Clin Oncol 2021, Aug 4.
Predictors of toxicity after neoadjuvant chemoradiotherapy for locally advanced gall bladder cancer. Indian J Cancer. 2021 Jan 27.
MRI and PET Guided Interstitial Brachytherapy for post-surgical Vaginal recurrences of cervical cancer: Results of Phase-II study. Int J Radiat Biol Phys. 2020. Feb 1.
Revision in Standard Operating Procedures of Radiation Oncology Department and Quality Assurance Schedule under COVID-19 Pandemic. J Med Phys. 2020 Apr-Jun;45(2):130-133.
Potential role of cancer stem cells as biomarkers and therapeutic targets in cervical cancer. Cancer Rep (Hoboken). 2019 Apr;2(2):e1144.
Neoadjuvant Chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stages IB2, IIA or IIB squamous cervical cancer: A Randomised Controlled Trial. J Clin Oncol 2018, Feb 12.
Cisplatinum Chemoradiotherapy versus Radiotherapy in FIGO stage IIIB Squamous Cell Carcinoma of the Uterine Cervix: A Randomised Controlled Trial. JAMA Oncol 2018 Feb 8.
Brachytherapy in India - a long road ahead. J Contemp Brachytherapy. 2014 Oct;6(3):331-5.
Prostate cancer: a hospital-based survival study from Mumbai, India. Asian Pac J Cancer Prev. 2013;14(4):2595-8.
Cosmesis, late sequelae and local control after breast-conserving therapy: influence of the type of tumour bed boost and adjuvant chemotherapy. Clin Oncol (R Coll Radiol). 2007 Oct;19(8):596-603
HIV infection and invasive cervical cancers, treatment with radiation therapy: toxicity and outcome. Radiother Oncol. 2005 Jan;74(1):31-5.
HCG - The Specialist in Cancer Care, India’s largest provider of cancer care, is at the forefront of the battle against cancer. Through its network of 21 comprehensive cancer centers, spread across India, HCG has brought advanced cancer care to the doorstep of millions of people.